Impact of fibrinogen concentrate alone or with prothrombin complex concentrate (+/− fresh frozen plasma) on plasma fibrinogen level and fibrin-based clot strength (FIBTEM) in major trauma: a retrospective study

Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine

Herbert Schöchl²  Marc Maegele³  Kenji Inaba¹  Wolfgang Voelckel²  Christoph J Schlimp⁴ 

[1] Department of Surgery, Los Angeles County and University of Southern California Medical Center, Los Angeles, CA, USA;Department of Anaesthesiology and Intensive Care Medicine, AUVA Trauma Centre, Salzburg, Austria;Department of Trauma and Orthopedic Surgery, University of Witten/Herdecke, Cologne-Merheim Medical Center (CMMC), Cologne, Germany;Ludwig Boltzmann Institute of Experimental and Clinical Traumatology, AUVA Research Centre, Vienna, Austria

关键词: Thromboelastometry (ROTEM);    Fresh frozen plasma;    Prothrombin complex concentrate;    Fibrinogen concentrate;   

Others  :  810677
DOI  :  10.1186/1757-7241-21-74

 received in 2013-07-18, accepted in 2013-10-04,  发布年份 2013

【 摘 要 】

Background

Low plasma fibrinogen concentration is a predictor of poor outcome in major trauma patients. The role of fibrinogen concentrate for rapidly increasing fibrinogen plasma levels in severe trauma is not well defined.

Methods

In this retrospective study we included severe trauma patients treated with fibrinogen concentrate alone (FC group), fibrinogen concentrate with prothrombin complex concentrate (FC–PCC group) or fibrinogen concentrate with PCC and fresh frozen plasma (FC–PCC–FFP group). PCC was generally administered as the second step of intraoperative therapy, while FFP was only administered as a third step. All patients received ≥1 g fibrinogen concentrate within 24 hours. Plasma fibrinogen concentration and ROTEM parameters upon emergency room (ER) admission, intensive care unit (ICU) admission, and after 24 hours were analysed.

Results

Among 157 patients fulfilling the inclusion criteria, 83% were male; mean age was 44 years and median injury severity score (ISS) was 29. Standard coagulation tests reflected increasing severity of coagulopathy with increasing complexity of haemostatic therapy (highest severity in the FC–PCC–FFP group; p < 0.0001). Total 24-hour fibrinogen concentrate dose also increased with complexity of haemostatic therapy. Plasma fibrinogen concentration was maintained, with no significant difference between ER admission and ICU admission in all patient groups. FIBTEM clot firmness at 10 minutes (CA₁₀) was similarly maintained, albeit with a small increase in the FC–PCC group. Fibrinogen concentration and FIBTEM CA₁₀ were within the normal range in all groups at 24 hours. The ratio of fibrinogen concentrate to red blood cells (g:U) ranged between 0.7:1.0 and 1.0:1.0.

Conclusion

Fibrinogen concentrate therapy maintained fibrinogen concentration and FIBTEM CA₁₀ during the initial phase of trauma care until ICU admission. After 24 hours, these parameters were comparable between the three groups and within the normal range for each of them. Further studies are warranted to investigate the effect of fibrinogen concentrate on clinical outcomes.

【 授权许可】

   
2013 Schlimp et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Kauvar DS, Wade CE: The epidemiology and modern management of traumatic hemorrhage: US and international perspectives. Crit Care 2005, 9(Suppl 5):S1-9. BioMed Central Full Text
• [2]Tien HC, Spencer F, Tremblay LN, Rizoli SB, Brenneman FD: Preventable deaths from hemorrhage at a level I Canadian trauma center. J Trauma 2007, 62:142-146.
• [3]Esposito TJ, Sanddal TL, Reynolds SA, Sanddal ND: Effect of a voluntary trauma system on preventable death and inappropriate care in a rural state. J Trauma 2003, 54:663-669.
• [4]Borgman MA, Spinella PC, Perkins JG, Grathwohl KW, Repine T, Beekley AC, Sebesta J, Jenkins D, Wade CE, Holcomb JB: The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma 2007, 63:805-813.
• [5]Ho AM, Dion PW, Yeung JH, Holcomb JB, Critchley LA, Ng CS, Karmakar MK, Cheung CW, Rainer TH: Prevalence of survivor bias in observational studies on fresh frozen plasma:erythrocyte ratios in trauma requiring massive transfusion. Anesthesiology 2012, 116:716-728.
• [6]Hiippala ST, Myllyla GJ, Vahtera EM: Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg 1995, 81:360-365.
• [7]Mosesson MW: Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005, 3:1894-1904.
• [8]Velik-Salchner C, Haas T, Innerhofer P, Streif W, Nussbaumer W, Klingler A, Klima G, Martinowitz U, Fries D: The effect of fibrinogen concentrate on thrombocytopenia. J Thromb Haemost 2007, 5:1019-1025.
• [9]Fries D, Innerhofer P, Reif C, Streif W, Klingler A, Schobersberger W, Velik-Salchner C, Friesenecker B: The effect of fibrinogen substitution on reversal of dilutional coagulopathy: an in vitro model. Anesth Analg 2006, 102:347-351.
• [10]Chambers LA, Chow SJ, Shaffer LE: Frequency and characteristics of coagulopathy in trauma patients treated with a low- or high-plasma-content massive transfusion protocol. Am J Clin Pathol 2011, 136:364-370.
• [11]Schlimp CJ, Voelckel W, Inaba K, Maegele M, Ponschab M, Schochl H: Estimation of plasma fibrinogen levels based on hemoglobin, base excess and Injury Severity Score upon emergency room admission. Crit Care 2013, 17(4):R137. BioMed Central Full Text
• [12]Schochl H, Cotton B, Inaba K, Nienaber U, Fischer H, Voelckel W, Solomon C: FIBTEM provides early prediction of massive transfusion in trauma. Crit Care 2011, 15:R265. BioMed Central Full Text
• [13]Tauber H, Innerhofer P, Breitkopf R, Westermann I, Beer R, El Attal R, Strasak A, Mittermayr M: Prevalence and impact of abnormal ROTEM® assays in severe blunt trauma: results of the 'Diagnosis and Treatment of Trauma-Induced Coagulopathy (DIA-TRE-TIC) study'. Br J Anaesth 2011, 107:378-387.
• [14]Theusinger OM, Baulig W, Seifert B, Emmert MY, Spahn DR, Asmis LM: Relative concentrations of haemostatic factors and cytokines in solvent/detergent-treated and fresh-frozen plasma. Br J Anaesth 2011, 106:505-511.
• [15]Rourke C, Curry N, Khan S, Taylor R, Raza I, Davenport R, Stanworth S, Brohi K: Fibrinogen levels during trauma hemorrhage, response to replacement therapy, and association with patient outcomes. J Thromb Haemost 2012, 10:1342-1351.
• [16]Nascimento B, Rizoli S, Rubenfeld G, Fukushima R, Ahmed N, Nathens A, Lin Y, Callum J: Cryoprecipitate transfusion: assessing appropriateness and dosing in trauma. Transfus Med 2011, 21:394-401.
• [17]Sorensen B, Bevan D: A critical evaluation of cryoprecipitate for replacement of fibrinogen. Br J Haematol 2010, 149:834-843.
• [18]Dickneite G, Pragst I, Joch C, Bergman GE: Animal model and clinical evidence indicating low thrombogenic potential of fibrinogen concentrate (Haemocomplettan P). Blood Coagul Fibrinolysis 2009, 20:535-540.
• [19]Rahe-Meyer N, Solomon C, Hanke A, Schmidt DS, Knoerzer D, Hochleitner G, Sorensen B, Hagl C, Pichlmaier M: Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial. Anesthesiology 2013, 118:40-50.
• [20]Grassetto A, De Nardin M, Ganzerla B, Geremia M, Saggioro D, Serafini E, Zampieri S, Toffoli M, Penzo D, Bossi A, Maggiolo C: ROTEM®-guided coagulation factor concentrate therapy in trauma: 2-year experience in Venice, Italy. Crit Care 2012, 16:428.
• [21]Grassetto A, Saggioro D, Caputo P, Penzo D, Bossi A, Tedesco M, Maggiolo C: Rotational thromboelastometry analysis and management of life-threatening haemorrhage in isolated craniofacial injury. Blood Coagul Fibrinolysis 2012, 23:551-555.
• [22]Schochl H, Forster L, Woidke R, Solomon C, Voelckel W: Use of rotation thromboelastometry (ROTEM) to achieve successful treatment of polytrauma with fibrinogen concentrate and prothrombin complex concentrate. Anaesthesia 2010, 65:199-203.
• [23]Schochl H, Nienaber U, Hofer G, Voelckel W, Jambor C, Scharbert G, Kozek-Langenecker S, Solomon C: Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care 2010, 14:R55. BioMed Central Full Text
• [24]Schochl H, Nienaber U, Maegele M, Hochleitner G, Primavesi F, Steitz B, Arndt C, Hanke A, Voelckel W, Solomon C: Transfusion in trauma: thromboelastometry-guided coagulation factor concentrate-based therapy versus standard fresh frozen plasma-based therapy. Crit Care 2011, 15:R83. BioMed Central Full Text
• [25]Schochl H, Posch A, Hanke A, Voelckel W, Solomon C: High-dose fibrinogen concentrate for haemostatic therapy of a major trauma patient with recent clopidogrel and aspirin intake. Scand J Clin Lab Invest 2010, 70:453-457.
• [26]Ziegler B, Schimke C, Marchet P, Stogermuller B, Schochl H, Solomon C: Severe Pediatric Blunt Trauma--Successful ROTEM-Guided Hemostatic Therapy with Fibrinogen Concentrate and No Administration of Fresh Frozen Plasma or Platelets. Clin Appl Thromb Hemost 2012. epub ahead of print
• [27]Schochl H, Schlimp CJ, Voelckel W: Potential value of pharmacological protocols in trauma. Curr Opin Anaesthesiol 2013, 26:221-229.
• [28]Spahn DR, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernandez-Mondejar E, Filipescu D, Hunt BJ, Komadina R, Nardi G, Neugebauer E, Ozier Y, Riddez L, Schultz A, Vincent JL, Rossaint R: Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care 2013, 17:R76. BioMed Central Full Text
• [29]Bolliger D, Szlam F, Molinaro RJ, Rahe-Meyer N, Levy JH, Tanaka KA: Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in vitro model. Br J Anaesth 2009, 102:793-799.
• [30]Martini WZ: Coagulopathy by hypothermia and acidosis: mechanisms of thrombin generation and fibrinogen availability. J Trauma 2009, 67:202-208.
• [31]Gando S, Sawamura A, Hayakawa M: Trauma, shock, and disseminated intravascular coagulation: lessons from the classical literature. Ann Surg 2011, 254:10-19.
• [32]Kashuk JL, Moore EE, Sawyer M, Wohlauer M, Pezold M, Barnett C, Biffl WL, Burlew CC, Johnson JL, Sauaia A: Primary fibrinolysis is integral in the pathogenesis of the acute coagulopathy of trauma. Ann Surg 2010, 252:434-442.
• [33]Schochl H, Frietsch T, Pavelka M, Jambor C: Hyperfibrinolysis after major trauma: differential diagnosis of lysis patterns and prognostic value of thrombelastometry. J Trauma 2009, 67:125-131.
• [34]Morrison JJ, Dubose JJ, Rasmussen TE, Midwinter MJ: Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study. Arch Surg 2012, 147:113-119.
• [35]Morrison JJ, Ross JD, Dubose JJ, Jansen JO, Midwinter MJ, Rasmussen TE: Association of cryoprecipitate and tranexamic acid with improved survival following wartime injury: findings from the MATTERs II study. JAMA Surg 2013, 148:218-225.
• [36]Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, Gando S, Guyatt G, Hunt BJ, Morales C, Perel P, Prieto-Merino D, Woolley T: The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 2011, 377:1096-1101.
• [37]Solomon C, Rahe-Meyer N: In reply. Transfusion 2013, 53:1138-1140.
• [38]Schreiber MA, Differding J, Thorborg P, Mayberry JC, Mullins RJ: Hypercoagulability is most prevalent early after injury and in female patients. J Trauma 2005, 58:475-481.
• [39]Innerhofer P, Westermann I, Tauber H, Breitkopf R, Fries D, Kastenberger T, El Attal R, Strasak A, Mittermayr M: The exclusive use of coagulation factor concentrates enables reversal of coagulopathy and decreases transfusion rates in patients with major blunt trauma. Injury 2013, 44:209-216.
• [40]Fenger-Eriksen C, Jensen TM, Kristensen BS, Jensen KM, Tonnesen E, Ingerslev J, Sorensen B: Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo-controlled clinical trial. J Thromb Haemost 2009, 7:795-802.
• [41]Karlsson M, Ternstrom L, Hyllner M, Baghaei F, Flinck A, Skrtic S, Jeppsson A: Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery. A prospective randomised pilot study. Thromb Haemost 2009, 102:137-144.
• [42]Solomon C, Hagl C, Rahe-Meyer N: Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery. Br J Anaesth 2013, 110:947-956.
• [43]Tanaka KA, Egan K, Szlam F, Ogawa S, Roback JD, Sreeram G, Guyton RA, Chen EP: Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion 2013. doi:10.1111/trf.12248
• [44]Meyer MA, Ostrowski SR, Windelov NA, Johansson PI: Fibrinogen concentrates for bleeding trauma patients: what is the evidence? Vox Sang 2011, 101:185-190.
• [45]Warmuth M, Mad P, Wild C: Systematic review of the efficacy and safety of fibrinogen concentrate substitution in adults. Acta Anaesthesiol Scand 2012, 56:539-548.
• [46]Schlimp CJ, Cadamuro J, Solomon C, Redl H, Schochl H: The effect of fibrinogen concentrate and factor XIII on thromboelastometry in 33% diluted blood with albumin, gelatine, hydroxyethyl starch or saline in vitro. Blood Transfus 2012, 1-9. doi: 10.2450/2012.0171-12
• [47]Grottke O, Braunschweig T, Spronk HM, Esch S, Rieg AD, van Oerle R, ten Cate H, Fitzner C, Tolba R, Rossaint R: Increasing concentrations of prothrombin complex concentrate induce disseminated intravascular coagulation in a pig model of coagulopathy with blunt liver injury. Blood 2011, 118:1943-1951.